SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Nektar
Therapeutics (NASDAQ:NKTR) announced today that it will host a
webcast analyst and investor conference call with a panel of
oncology experts and company management on Wednesday, November 11, 2020, at 4:15 p.m. EST during the 2020 Society for
Immunotherapy of Cancer Annual Meeting (SITC). The call will be
hosted by Nektar management and will include SITC authors and
presenters, Dr. Adi Diab, Associate
Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center; Dr.
Brendan Curti, Director of the
Melanoma Program, Cytokine and Adoptive Immunotherapy and
Genitourinary Oncology Research at Providence Cancer Institute; and
Dr. Nina Shah, Associate Professor,
Department of Medicine, at the University of
California San Francisco.
The event will follow the SITC 2020 presentations on Wednesday
which will include clinical data for three Nektar-sponsored
studies, including updated clinical data from a cohort of
first-line Stage IV metastatic melanoma patients in the PIVOT-02
study of bempegaldesleukin (NKTR-214; BEMPEG) with nivolumab, as
well as presentations about Nektar's NKTR-255 and NKTR-262
programs. The 2020 SITC Annual Meeting is being held virtually from
November 9 to November 14, 2020.
Analyst Call with Panel of Oncologists:
Date and Time: Wednesday, November 11, 2020, at
4:15 p.m. EST
Dial-in: 877-881-2183 (toll-free) or 970-315-0453
(enter access code 2090614)
Investors and analysts can also view slides and listen to the
live audio webcast of the presentation at
https://edge.media-server.com/mmc/p/25u4g5o7. The event will also
be available for replay for two weeks on the company's website,
www.nektar.com.
Details of the presentations at SITC are as follows:
Nektar Oral and Poster Presentations at SITC
Abstract 355: "First-in-human phase I study of
NKTR-255 in patients with relapsed/refractory hematologic
malignancies", Shah, N., et al.
- Poster will be available on November
9th at 8:00 AM
EST
- Poster Session Date and Time: Wednesday, November 11th,
2020, from 5:15 p.m. - 5:45 p.m.
EST
Abstract 368: "REVEAL: Phase 1 dose-escalation
study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin:
local innate immune activation and systemic adaptive immune
expansion for treating solid tumors", Diab, A., et al.
- Oral Session Title: Combinatorial Therapies
- Presenter: Dr. Adi Diab,
MD Anderson Cancer Center
- Date: Wednesday, November
11th, 2020, from 11:15
a.m. – 1:10 p.m. EST
Abstract 420: "Progression-free survival and
biomarker correlates of response with BEMPEG plus NIVO in
previously untreated patients with metastatic melanoma: results
from the PIVOT-02 study", Diab, A., et al.
- Oral Session Title: Concurrent Rapid Oral Abstract
Presentation Session: Clinical
- Presenter: Dr. Adi Diab,
MD Anderson Cancer Center
- Date: Wednesday, November
11th, 2020, from 1:30
p.m. – 2:00 p.m. EST
Additional Collaborator Presentations at SITC
Abstract 451: "Combining Bempegaldesleukin
(CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8
agonist) pairs local innate activation with systemic CD8+ T cell
expansion to enhance anti-tumor immunity", Rolig, A., et
al.
- Poster will be available on November
9th at 8:00 AM
EST
- Poster Session Date and Time: Wednesday, November 11th,
2020, from 5:15 p.m. - 5:45 p.m.
EST
Dr. Adi Diab
Adi Diab, M.D., serves as
Associate Professor of Melanoma Medical Oncology at the
University of Texas MD Anderson Cancer
Center. Dr. Diab is one of the lead investigators in PIVOT-02, the
Phase 1/2 study of bempeg plus nivolumab, and in REVEAL, the Phase
1/2 study of NKTR-262 and bempeg. He is also in the steering
committee for the BMS-sponsored Phase 3 registrational study, which
is ongoing in patients with previously untreated metastatic
melanoma. His research is focused on developing new
immunotherapeutic strategies that will improve clinical outcomes in
patients. He has authored or co-authored over thirty scientific
publications and abstracts and serves as a reviewer for the Cancer
Discovery, Journal of Clinical Oncology, Nature Reviews Journal of
Immunotherapy and the Journal of the American Society of
Hematology.
Dr. Brendan D. Curti
Brendan D. Curti, M.D., is the
Robert W. Franz Chair for Clinic Research and Member in the Earle
A. Chiles Research Institute at Providence Cancer Institute. He
serves as the Director of Cytokine and Adoptive Immunotherapy,
Melanoma Program and Genitourinary Oncology Research. His clinical
research focuses on developing new immunotherapies for melanoma,
renal cell carcinoma, prostate cancer and bladder cancer. He
previously served as a Senior Investigator in the Biological
Response Modifiers Program at the National Cancer Institute and was
an Associate Professor at the Penn State
College of Medicine before joining Providence Cancer
Institute.
Dr. Nina Shah
Nina Shah, M.D., is an Associate
Professor in the Department of Medicine at the University of California San Francisco and a
specialist in blood diseases who focuses on treating multiple
myeloma, a type of cancer affecting certain cells in the bone
marrow. Her areas of professional interest include the intersection
of immunology and oncology as well as helping patients fight
multiple myeloma by boosting their immune systems. She belongs to
the American Society of Clinical Oncology, American Society of
Hematology and American Society for Transplantation and Cellular
Therapy.
About Nektar
Nektar Therapeutics is a biopharmaceutical company with a
robust, wholly owned R&D pipeline of investigational medicines
in oncology, immunology and virology well as a portfolio of
approved partnered medicines. Nektar is headquartered in
San Francisco, California, with
additional operations in Huntsville,
Alabama and Hyderabad,
India. Further information about the company and its drug
development programs and capabilities may be found online at
http://www.nektar.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements which can
be identified by words such as: "will," "develop," "may" and
similar references to future periods. Examples of forward-looking
statements include, among others, statements we make regarding the
therapeutic potential of bempegaldesleukin in combination with
nivolumab, and the therapeutic potential of each of NKTR-255 and
NKTR-262, as well as the availability of results and outcomes from
clinical and preclinical studies of our drug candidates.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated
events and trends, and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results may differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important
factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include,
among others: (i) our statements regarding the therapeutic
potential of our drug candidates are based on preclinical and
clinical findings and the expected therapeutic potential for each
of our drug candidates is subject to change as research and
development continue; (ii) our drug candidates are in clinical
development and the risk of failure remains high and failure can
unexpectedly occur at any stage for one or more of the indications
being studied prior to regulatory approval due to lack of
sufficient efficacy, safety considerations or other factors that
impact drug development; (iii) data reported from ongoing
preclinical and clinical trials are necessarily interim data only
and the final results will change based on continuing observations;
(iv) scientific discovery of new medical breakthroughs is an
inherently uncertain process and the future success of potential
new drug candidates (such as bempegaldesleukin, NKTR-255 and
NKTR-262) is therefore very uncertain and unpredictable; (v) the
timing of the commencement or end of clinical studies and the
availability of clinical data may be delayed or unsuccessful due to
regulatory delays, slower than anticipated patient enrollment,
manufacturing challenges, changing standards of care, evolving
regulatory requirements, clinical trial design, clinical outcomes,
delays caused by our collaboration partners, and enrollment
competition; (vi) patents may not issue from our patent
applications for our drug candidates, patents that have issued may
not be enforceable, or additional intellectual property licenses
from third parties may be required; and (vii) certain other
important risks and uncertainties set forth in Nektar's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on November 6, 2020. Any
forward-looking statement made by us in this press release is based
only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
For Investors:
Jerry Isaacson of Nektar
Therapeutics
628-895-0634
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Dan Budwick of 1AB
dan@1abmedia.com
973-271-6085
View original
content:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-webcast-conference-call-for-analysts--investors-with-expert-oncologist-panel-during-2020-society-for-immunotherapy-of-cancer-sitc-35th-annual-meeting-301168349.html
SOURCE Nektar Therapeutics